Sanofi shuts down factory over toxic waste outcry

July 10, 2018 by Etienne Balmer
French pharmaceutical Sanofi shut down its Mourenx plant after an environmental watchdog group claimed that the site has been emitting "dangerous material at astronomical levels"

French pharmaceuticals group Sanofi announced late Monday an immediate halt in production at a chemical factory in southwest France, in the wake of media reports that toxic waste emissions exceeded the norms.

"Sanofi Chemical has decided from today to stop production at its Mourenx and to carry out the announced technical improvements needed to return to normal," the group said in a brief statement.

It added that it was conducting an internal inquiry "to better understand the causes and history of the situation."

Earlier Monday, Sanofi had admitted there was "a problem of exceeding the threshold for the vapour waste of solvents," but it insisted that the local population was not exposed to levels higher than those laid down by regulation, a finding it said was determined by an independent health impact study.

The Mourenx factory with around 50 employees has been at the heart of an environmental outcry since Sunday.

France Nature Environment (FNE) said in a statement that the site has been emitting "dangerous material at astronomical levels".

FNE, a federation of some 3,500 environmental associations, claims that in reality the factory's emissions are "7,000 times more than the authorised norm... sending astronomical quantities of pollutants into the air".

FNE and a local group Sepanso 64 had demanded the immediate shutdown of the factory, noting in particular that the compound bromopropane in the emissions can hurt fertility or the foetus, and also irritate a person's respiratory system and the skin.

Sanofi meanwhile said that it has already instituted an action plan to collect and treat the waste to significantly reduce it and that it had planned 10 days ago to carry out summer maintenance of the site.

Explore further: US firm Advent to buy Sanofi's generics unit

Related Stories

US firm Advent to buy Sanofi's generics unit

April 17, 2018
US private equity firm Advent International has agreed to acquire Zentiva, French pharmaceutical giant Sanofi's European generics arm, for 1.9 billion euros ($2.4 billion), a statement said Tuesday.

Sanofi builds $75 mn factory in Vietnam for ASEAN markets

March 29, 2013
French drugmaker Sanofi said Friday that it had begun building a new manufacturing facility in Vietnam to serve the expanding pharmaceutical market in southeast Asia.

France's Sanofi buys biotech company Ablynx for $4.8 billion

January 29, 2018
French drugmaker Sanofi has made another big purchase aimed at strengthening its position in rare disease treatments, buying Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion).

Sanofi sues US company over diabetes drug patent rights

October 25, 2017
French drugmaker Sanofi said it is suing a US pharmaceuticals company for allegedly infringing the patent on its key insulin treatment as sales of its diabetes drugs are falling.

France's Sanofi faces class action suit over epilepsy drug

December 13, 2016
An association of French women who took an epilepsy drug during pregnancy said Tuesday they would launch a class action against its maker, Sanofi.

Sanofi buys US flu vaccine maker Protein for $750 mln

July 11, 2017
French pharmaceuticals giant Sanofi, which is looking to boost its presence in biotechnology, said Tuesday it had agreed to buy the privately-owned US vaccines maker Protein Sciences for up to $750 million (658 million euros).

Recommended for you

Drug overdose epidemic has been growing exponentially for decades

September 20, 2018
Death rates from drug overdoses in the U.S. have been on an exponential growth curve that began at least 15 years before the mid-1990s surge in opioid prescribing, suggesting that overdose death rates may continue along this ...

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.